H. Lundbeck A/S

H. Lundbeck A/S

HLUBF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$8.28B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
H. Lundbeck A/SH. Lundbeck A/S14.51.94%14%0.30.3

Earnings Call Q3 2026

November 11, 2026 - AI Summary

Strong business momentum; guidance raised (core forecast) - Management is confident enough to raise full-year guidance: Revenue growth: +11–12% and Adjusted EBITDA growth: +15–19% (both at constant exchange rates). - Q3/Q3-to-date visibility improved due to strong Vyepti performance and partner markets performing better than expected, plus more certainty on R&D phasing. - Guidance detail/changing assumptions: R&D spending level now expected at DKK 5.6–5.7bn; adjusted gross margin expected 86–87%; effective tax rate 21–24%. - The EBITDA uplift is partly timing/phasing-driven, not “true saving”: management said EBITDA growth is primarily from revenue/gross profit, with some timing effects in R&D.
Commercial outperformance: Viepti and Rexulti driving growth - Viepti (eptinezumab): major growth engine - Through 9 months 2026 global revenue: DKK 4.533bn (+45% at CER). - US growth: +46% at CER; Viepti is growing faster than the anti-CGRP market (Viepti demand +39.3% vs market +15.6%). - Growth drivers cited: new patient starts, conversion, and best-in-class persistency; marketing investments supported by advanced analytics/AI. - Europe/international: +41% at CER, gaining >2pp market share YoY (notably France and Spain). - Japan milestone: marketing approval received; launch planned by end of 2026. - Rexulti (brexpiprazole): resilient + adds mix/segment tailwinds - 9 months 2026 global revenue: DKK 5.1bn (+13% at CER). - US: TRx demand +15.1% YoY through Aug; AAD driving growth (+29% YoY). - MDD: TRx +13.7% YoY. - 65+ segment: 37% of total Rexulti TRx, expanding—management views this as supportive for long-term uptake despite competition.
R&D/pipeline: multiple clinical catalysts and platform-building strategy (opportunities) - Management reiterated a “scale phase” coming after successfully completing the focus innovator strategy (3 pillars: growth, funding, innovation). They claim the pipeline is on track for milestones, including 5–6 mid-to-late-stage assets. - Bexicasiran (DEE/Dravet & related): pivotal near-term - Phase 3 headline results expected end of Q4. - Regulatory aligned BID dosing plan as a post-approval label update (trial currently on TID; switch planned after approval). - Mechanism explanation: highly selective 5-HT2C agonist aiming to reduce hyperexcitability across diverse DEE biology; breakthrough therapy designation referenced. - Bocunebart (PACAP antibody, migraine prevention) - Phase 2b PROCEED: 5.9-day reduction in monthly migraine days vs baseline (chronic migraine with prior preventive failure). - Phase 3 planned (management: initiate this quarter / end of year). - Amlinetug / MSA - Phase 3 “largest interventional trial ever” in MSA; baseline presented; pivotal headline results expected in Q3 2027. - Asedebart (anti-ACTH, Cushing’s) - Enrollment completed for Phase 2 BALANCE; orphan drug designations (FDA + EC); strong early Phase 3 UFC normalization signal described. - Regulatory momentum: by Q3 close, 11 orphan drug / 3 fast track / 2 breakthrough designations (up from 14 special designations at half-year), totaling 16.

Exclusive for Stockcircle Pro members

Sign upSign Up

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$8.28 Billion
Enterprise Value$13.27 Billion
Annual dividend$0.18
Dividend yield1.94%
Earnings per Share$3.21
Beta0.26
Outstanding Shares992,149,181

Return

Return on Equity14.32%ROE
Return on Assets7.51%
Return on Invested Capital15.17%

Valuation & Multiples

P/E Ratio14.54P/E Ratio
PEG96.41PEG
Price to Sales0.32Price to Sales
Price to Book Ratio0.3Price to Book Ratio
Enterprise Value to Revenue0.51
Enterprise Value to EBIT1.99
Enterprise Value to Net Income3
Total Debt to Enterprise0.65
Debt to Equity0.31Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 11, 2026
EPS Estimate
-
Consensus analyst estimate
Revenue Estimate
$956.74 M
Consensus analyst estimate

Next Earnings Call

Expected Date
February 10, 2027
EPS Estimate
-
Consensus analyst estimate
Revenue Estimate
$928.54 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About H. Lundbeck A/S

5,214 employees
CEO: Charl van Zyl

H. Lundbeck A/S operates as an international biopharmaceutical entity, focusing its efforts on the entire lifecycle of pharmaceutical products—from initial research and development to manufacturing and global sales. The firm primarily sp...